$3.45 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Clene

Clene Inc, formerly Chelsea Worldwide Inc., is a clinical-stage biopharmaceutical company. The Company through its subsidiary, Clene Nanomedicine, Inc., is focused on the development of therapeutics for neurodegenerative diseases. The Company has innovated a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. It has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. The Company’s pipeline includes CNM-Au8, CNM-ZnAg, CNM-AgZn-17 and CNM-AuPt7. Its CNM-Au8 is a bioenergetic nanocatalyst, which enhances critical intracellular bioenergetic reactions necessary for repairing and reversing neuronal damage. CNM-AgZn17 is a topical gel polymer suspension of silver and zinc ions. Its CNM-PtAu7 is gold-platinum clean surfaced nanotechnology (CSN) therapeutic, which aims to address the unmet medical needs in several disease areas.

Stock Analysis

last close $3.4
1-mo return 21.4%
3-mo return 29.8%
avg daily vol. 3.25M
52-week high 9.17
52-week low 1.93
market cap. $230M
forward pe -
annual div. -
roe -150.6%
ltg forecast -
dividend yield -
annual rev. $1M
inst own. 9.5%

Subscribe now for daily local and international financial news